Australia Confronts Rising "Superbug" Threat: Calls for Innovative Funding to Combat Antimicrobial Resistance

Australia is facing an escalating crisis from antimicrobial resistance (AMR), commonly known as "superbugs," which are rendering existing treatments ineffective against infections. This poses a severe threat to public health, marked by increasing infection rates, a dwindling supply of new antibiotics, and significant economic disincentives for pharmaceutical development. Experts and advocacy groups are now proposing innovative funding models, such as a subscription model for new antibiotics, to address these critical challenges.

The Scope of Antimicrobial Resistance

AMR occurs when bacteria, viruses, fungi, and parasites develop resistance to antimicrobial medications, making infections increasingly difficult or even impossible to treat. This phenomenon has profound implications for modern medicine, as it can transform common infections into life-threatening conditions and heighten the risks associated with routine medical procedures like surgeries and cancer treatments.

The Australian and Global Toll

Estimates for annual deaths in Australia due to resistant infections vary significantly, ranging from 1,600 fatalities in one report to approximately 5,200 annually (based on 100 deaths weekly) in another. Projections indicate that Australian deaths could surge to 10,000 annually by 2050 if this issue remains unaddressed. Globally, AMR is projected to cause a staggering 10 million deaths annually by the same year. Critically ill patients and newborns are identified as particularly vulnerable groups.

The Australian Centre for Disease Control (ACDC) has officially designated AMR as an urgent global public health threat. Reports in 2024 revealed an alarming increase of over 25 percent in critical antibiotic resistance across Australia. Data further illustrates the severity of the problem, showing that multidrug-resistant bacteria were present in 12.2 percent of bloodstream infections in children.

"AMR is an urgent global public health threat, with Australian deaths projected to rise to 10,000 annually by 2050 if the issue remains unaddressed."

Lagging Behind: Challenges in Treatment and Development

The rate at which AMR is evolving is reportedly outpacing the development of new medications. A particular challenge exists within paediatrics, where fewer novel antibiotics are licensed for children compared to adults.

Globally, out of 25 new antibiotics approved in the US and Europe since 2011, a mere three are registered for use in Australia. Another report highlights an even starker disparity, indicating that of 23 new antibiotics approved worldwide since 2013, only two are approved for use in Australia. This scarcity necessitates approximately 500 monthly applications from clinicians to access unregistered antibiotics, with 27 percent of these requests pertaining to critically ill patients.

Drivers of Resistance: Why Superbugs Thrive

Several interconnected factors contribute to the escalating rise of antibiotic resistance and the stalled development of urgently needed new drugs:

• Bacterial Evolution: Bacteria possess rapid evolutionary capabilities, readily sharing genetic information that enables them to adapt and survive exposure to antibiotics.
• Antibiotic Overuse: Australia records high rates of human antibiotic prescriptions, with approximately two-thirds of global prescriptions considered unnecessary.
• Diagnostic Gaps: The absence of rapid diagnostic tools frequently leads to antibiotics being prescribed preemptively for infections that may be viral rather than bacterial, thus ineffective.
• Perception of Safety: Antibiotics are often perceived as universally safe, yet they can have significant side effects impacting hearing, muscles, kidneys, and beneficial microbiota.
• Agricultural Use: Globally, a substantial portion (around two-thirds) of antibiotics are used in animal agriculture, often for growth promotion. Australia, however, reports comparatively lower agricultural antibiotic use compared to international averages.

The Economic Hurdle for New Antibiotics

The development of new antibiotics faces significant economic disincentives, contributing directly to a reduced pipeline of new treatments:

• Profitability Concerns: Major pharmaceutical companies have largely scaled back early-stage antibiotic discovery efforts. New, potent antibiotics are often intended for sparing use to preserve their effectiveness, which inherently limits their market reach and profitability.
• Market Valuation: The market valuation for life-saving antibiotics (estimated at approximately $15,000 per course) is significantly lower than that of some cancer therapies, which can reach up to $500,000.
• Investment Decline: Venture capital investment in antibiotic development has notably decreased. This has resulted in a limited number of antibiotics currently in human trials (50-60) compared to other drug classes like cancer treatments (thousands).

Access Issues and Policy Fragmentation

Lower-income countries frequently encounter difficulties affording new antibiotics. Smaller high-income countries, including Australia, face prohibitively high registration costs for new drugs that can often exceed their potential sales in these markets.

In Australia, the responsibility for addressing antibiotic resistance is currently distributed across various government departments, leading to calls for more coordinated and consolidated efforts. The Australian Antimicrobial Resistance Network (AAMRNet) actively advocates for change, operating with variable funding.

Innovative Solutions: A Path Forward

The Australian Antimicrobial Resistance Network (AAMRNet) is advocating for Australia to adopt a "subscription model" for antimicrobials.

The Subscription Model

Under this proposed model, the federal government would pay pharmaceutical companies a fixed annual fee for access to novel antibiotics, regardless of their usage rates. This approach aims to incentivize pharmaceutical companies to invest in the research and development of new antibiotics by providing a predictable and stable revenue stream.

The United Kingdom's existing subscription model serves as a pioneering example, where the National Health Service (NHS) pays between £5 million and £20 million per drug annually. This scheme has reportedly secured access to two new antibiotics, Cefiderocol and Ceftazidime-avibactam, crucial for treating severe, multidrug-resistant Gram-negative infections. This model is seen as a vital mechanism to address a market failure where antibiotics, due to their short duration of use, are less profitable than drugs for chronic conditions. Proponents suggest that wider adoption of such models could re-engage the industry in antibiotic development. However, it is strongly emphasized that rigorous stewardship must accompany any subscription model to prevent new antibiotics from rapidly becoming ineffective due to overuse.

Broader Funding and Collaboration

Other proposed solutions include:

• Increased funding for antibiotic research and development infrastructure within Australia.
• Active participation in global initiatives such as CARB-X and GARDP, which currently fund Australian research without direct financial contributions from Australia.
• Strengthened research funding through established bodies like the National Health and Medical Research Council (NHMRC) and strategic utilization of unspent funds from the Medical Research Future Fund (MRFF).

A spokesperson for the Albanese government has affirmed its commitment to minimizing the development and spread of AMR and ensuring the continued availability of effective antimicrobials.